perioperative management of glp 1 agonists 🔸 Should GLP-1 RAs be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? Read: https://doi.org/10.1097/01.ASM.0001125664.22893.9f Glucagon-Like Peptide-1 Receptor Agonists in

Syn NL, Cummings DE, Wang LZ, et al

But the same mechanisms that make these drugs effective can also cause gastrointestinal side effects such as: Nausea Vomiting Diarrhea Reduced appetite All of these symptoms can contribute to lower fluid intakeor increased fluid losswhich is a fast track to dehydration

Knudsen LB, Nielsen PF, Huusfeldt PO et al

After 2 weeks of treatment, the dose should be increased to 0.2 mg (100 l) three times daily

Consistent with the metabolic improvements discussed previously, current evidence supports the premise that GLP-1RAs promote SHBG synthesis and reduce bioavailable free androgen activity primarily through weight loss and the alleviation of IR

51-OR: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of BI 456906 in people with overweight/obesity